Elisabeth Bjork - 02 Jan 2026 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Reporting relationship: Director
Issuer ticker: RCKT
Reported as of: 02 Jan 2026
Net transaction value: +$34,400
SEC form: 4
Accepted by SEC: 06 Jan 2026, 16:05:11 UTC
Prior SEC filing: 27 Aug 2025
Next SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Martin Wilson, as attorney-in-fact for Elisabeth Bjork

Key filing fact

Elisabeth Bjork filed Form 4 for ROCKET PHARMACEUTICALS, INC. (RCKT) on 06 Jan 2026.

Key facts

This page summarizes Elisabeth Bjork's Form 4 filing for ROCKET PHARMACEUTICALS, INC. (RCKT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 06 Jan 2026, 16:05.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

CIK 0001810406 Primary reporting owner

Shares, units, or other non-derivative securities reported in this filing.

RCKT transaction

Purchase

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Explanation of responses 1 footnote

Footnote F1

Includes 30,000 restricted stock units ("RSUs") that convert to common stock on a one-for-one basis and vest in full on June 18, 2026.